- Bioidentical means structurally identical to the hormone your body makes. It does not mean natural, and it does not mean risk-free.
- The panel comes first, always. Prescribing hormones without measuring thyroid, iron, insulin and inflammation alongside is how patients end up disappointed.
- Route genuinely changes risk. Transdermal estradiol does not carry the clotting risk of oral, because it bypasses first-pass liver metabolism.
- Micronised progesterone is not medroxyprogesterone. The synthetic progestin used in the WHI has a different profile from the bioidentical form — a distinction the headlines never made.
- Timing matters more than almost anything. Starting within roughly ten years of menopause produces a very different risk-benefit picture from starting twenty years later.
What "bioidentical" actually means
Patients arrive using this word all the time, and it has been marketed loosely enough to be nearly meaningless. It has a precise definition, and I want you to have it.
A bioidentical hormone is structurally identical to the hormone your body produces. Estradiol prescribed as estradiol is bioidentical. Micronised progesterone is bioidentical. Testosterone cypionate converts to bioidentical testosterone.
By contrast, medroxyprogesterone acetate — the progestin used in the Women's Health Initiative — is not progesterone. It is a synthetic molecule that binds the progesterone receptor and produces some of the same effects and some different ones. Conjugated equine estrogens are likewise not human estradiol.
Two clarifications, because both are frequently misrepresented. Bioidentical does not mean natural — these are synthesised in a laboratory, usually from plant sterols. And bioidentical does not mean risk-free. A hormone identical to your own still carries the effects of that hormone at the dose given. Anyone selling bioidenticals as inherently safe is overstating it.
What is fair to say is that the distinction is real and clinically meaningful — particularly for progesterone, where the bioidentical form has a more favourable profile than the synthetic used in the trial that shaped a generation of prescribing.
The panel that has to come first
This is where we differ most from a hormone clinic that will see you and prescribe on the same afternoon.
Hormone symptoms are not specific. Fatigue, weight gain, low mood, poor sleep, brain fog and low libido are produced by hormone decline — and equally by hypothyroidism, iron deficiency, insulin resistance, sleep apnoea and chronic inflammation.
If you prescribe hormones to a woman whose actual problem is a ferritin of 14 and a free T3 at the floor, she gets a modest benefit, an ongoing prescription and no resolution. We see that pattern constantly.
The honest risk conversation
Every patient arrives with a version of the WHI in their head, usually from a headline rather than the reanalysis. Here is where it genuinely stands.
The 2002 Women's Health Initiative report caused a collapse in prescribing that reshaped women's health for two decades. The reanalysis since has changed the picture substantially, and three things matter most.
Timing. The average WHI participant was 63 and more than a decade past menopause. For healthy women beginning within roughly ten years of their final period, the risk-benefit balance looks materially different.
Formulation. The trial used conjugated equine estrogens with medroxyprogesterone acetate. Neither is bioidentical, and micronised progesterone in particular has a more favourable profile.
Route. Oral estrogen passes through the liver first, which is where the clotting risk is generated. Transdermal delivery bypasses that and does not carry the same venous thromboembolism signal.
What has not changed: hormone therapy is not right for everyone. Personal history of breast cancer, active clotting disorder, unexplained bleeding and certain cardiovascular conditions all change the conversation. And for anyone with a hormone-sensitive cancer history, this is an entirely different discussion that belongs with your oncology team.
Why delivery route changes the picture
The same hormone at the same dose behaves differently depending on how it enters your body. This is not a detail.
Transdermal — creams, gels and patches. Absorbed through skin into circulation, bypassing first-pass liver metabolism. This is why transdermal estradiol does not carry the clotting risk that oral does. Our default for estrogen in most cases.
Oral — appropriate for micronised progesterone, where the first-pass metabolites contribute to its sedating effect, which is genuinely useful when sleep is part of the picture.
Injection — standard for testosterone in men, allowing precise dosing and reliable levels. Frequency matters: smaller, more frequent doses produce steadier levels than large fortnightly ones.
Pellets — convenient, and the route we are most cautious about. Once implanted the dose cannot be adjusted for months, and supraphysiological levels are a recognised problem. Where someone arrives on pellets with a total testosterone of 1,200, the pellet is usually the reason.
The ten things that decide whether hormone therapy works
Ranked by how often each one determines the outcome.
Running the Full Panel First
The single biggest determinant. Hormone symptoms overlap almost entirely with thyroid, iron, insulin and inflammatory problems. Prescribing without measuring those means treating the wrong thing at best and masking it at worst.
What the evidence showsHormone symptoms overlap substantially with hypothyroidism, iron deficiency, insulin resistance and sleep disorders. Prescribing without excluding those produces partial response and an ongoing prescription treating the wrong problem.Choosing the Right Route
Transdermal estradiol does not carry the clotting risk that oral does, because it bypasses first-pass liver metabolism. This single decision changes the risk profile more than most of what follows it.
What the evidence showsCananico and colleagues demonstrated in Circulation that transdermal estradiol was not associated with the venous thromboembolism risk seen with oral estrogen, because it bypasses first-pass hepatic metabolism.Using Micronised Progesterone
Rather than a synthetic progestin. Better profile, genuinely sedating in a way that helps sleep, and it is the form that the WHI did not test. Needed in anyone with a uterus receiving estrogen.
What the evidence showsMicronised progesterone has a different metabolic and breast tissue profile from medroxyprogesterone acetate, the synthetic progestin used in the Women's Health Initiative. Its metabolites also produce genuine sedation useful for sleep.Correcting Iron and Thyroid First
A woman with a ferritin of 14 and a free T3 at the floor will get a modest response to hormones and conclude they did not work. Fixing those first frequently resolves half the symptom list before a hormone is prescribed.
What the evidence showsFerritin below 30 ng/mL and low free T3 both produce fatigue, low mood and cognitive symptoms indistinguishable from hormone decline, and both are common in the same demographic.Not Overshooting the Dose
The most common error we correct in patients arriving from elsewhere. Supraphysiological testosterone suppresses HDL, raises haematocrit, aromatises to estrogen and slows thyroid conversion. More is emphatically not better.
What the evidence showsSupraphysiological testosterone raises haematocrit, suppresses HDL, increases aromatisation to estradiol and impairs thyroid conversion. The Endocrine Society guideline specifies monitoring parameters for this reason.Retesting and Titrating
Hormones are dosed to a target, and the only way to know you are at it is to measure. Anyone prescribing without a follow-up panel is guessing, and pellets make this harder because the dose cannot be adjusted mid-course.
What the evidence showsHormone dosing requires titration to measured levels. Pellet delivery cannot be adjusted after implantation, which is why supraphysiological levels are more commonly encountered with that route.Addressing Insulin
Insulin suppresses SHBG, which changes how much free hormone circulates from any given dose. Two women on identical prescriptions can have very different free levels because of it.
What the evidence showsInsulin suppresses hepatic SHBG synthesis, altering the free fraction of circulating hormone. Identical prescribed doses therefore produce different free hormone levels depending on metabolic status.Supporting Estrogen Clearance
How estrogen is metabolised and cleared matters as much as how much is given. Cruciferous vegetables, adequate fibre, healthy gut flora and good liver function all shape the metabolite profile.
What the evidence showsEstrogen metabolism proceeds through competing hydroxylation pathways, and the metabolite ratio is influenced by cruciferous vegetable intake, gut beta-glucuronidase activity and hepatic methylation capacity.Screening Every Botanical
Where hormone-sensitive cancer history exists, phytoestrogens are excluded — black cohosh, red clover and soy isoflavones. Ground flax lignans remain appropriate because they are anti-estrogenic. This screening happens before anything is prescribed.
What the evidence showsBlack cohosh, red clover and soy isoflavones are phytoestrogenic and are excluded where hormone-sensitive cancer history exists. Ground flax lignans are anti-estrogenic and remain appropriate.Knowing When Not To
Some patients should not be on hormone therapy, and some arriving on it should be tapered rather than continued. Being willing to say that is the difference between a clinic and a dispensary.
What the evidence showsThe 2022 North American Menopause Society position statement specifies contraindications and the populations in whom hormone therapy is not appropriate, including personal history of breast cancer and active thromboembolic disease.What patients commonly experience under our care
When patients receive the proper guidance, here is what they commonly experience under our care.
- Weeks 1–2 — sleep and vasomotor symptoms. Progesterone affects sleep almost immediately, and hot flushes typically respond within the first fortnight. These are the fastest changes and the ones that make everything else tolerable.
- Weeks 3–6 — mood, clarity and libido. Downstream of sleep and of steadier hormone levels. In men on testosterone, motivation and drive usually shift in this window before anything physical does.
- Weeks 6–12 — the panel, and the first titration. We retest here. Free hormone levels against target, SHBG, haematocrit in men, and a lipid panel. This is where the dose gets adjusted — and it is why we are cautious about routes that cannot be adjusted.
- Months 3–6 — body composition and bone. The slowest and most durable effects. Muscle mass, fat distribution and bone density respond over quarters rather than weeks, and only alongside protein and resistance training.
Before you start hormones — or if you are already on them and still not right — schedule a consultation. My team will run the full picture, find what is actually driving your symptoms, and make sure any hormone therapy you receive is built on a foundation that will hold. That is world-class care, and it is what every patient deserves.
We measure thyroid, iron, insulin and inflammation alongside your hormones — because those four decide whether hormone therapy will actually work for you.
Common questions
What does bioidentical actually mean?
It means the hormone is structurally identical to the one your body produces. Estradiol, micronised progesterone and testosterone are bioidentical; medroxyprogesterone acetate and conjugated equine estrogens are not. It does not mean natural, and it does not mean risk-free — a hormone identical to your own still has that hormone's effects at the dose given.
Is bioidentical hormone therapy safer than conventional HRT?
In specific, meaningful ways — but the framing matters. Micronised progesterone has a more favourable profile than the synthetic progestin used in the WHI, and transdermal estradiol does not carry the clotting risk of oral. Those are genuine differences. What is not true is that bioidentical hormones are inherently safe. Route, dose, timing and your own history all matter more than the word itself.
Do I need a blood test before starting hormones?
We would say yes, without exception, and a broader one than most clinics run. Hormone symptoms overlap almost completely with thyroid dysfunction, iron deficiency, insulin resistance and inflammation. Prescribing without measuring those means you may be treating the wrong problem entirely.
Are hormone pellets a good option?
They are convenient, and that is their main advantage. Our caution is that once implanted the dose cannot be adjusted for months, and supraphysiological levels are a well-recognised problem with them. When a patient arrives with a total testosterone of 1,200, pellets are very often the reason. We prefer routes we can titrate.
Can I do hormone therapy if I've had breast cancer?
That is a conversation for you and your oncology team, and it is a genuinely different discussion from the one on this page. What we can say is that we screen every botanical and every therapy for phytoestrogens in anyone with a hormone-sensitive cancer history, and that suppressed hormone levels in that context are usually intentional and protective rather than a deficiency to correct.
- Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927–938. PMID 28898378
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2007;115(7):840–845.
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
This article is educational and reflects the published literature as of August 2026. It is not a diagnosis or a treatment recommendation for any individual, and any decision about your care belongs in a conversation with a licensed practitioner who has seen your history and your labs.